TELESIS BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3184 USD | -0.93% |
|
+3.04% | -20.20% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 316.5 | 35.43 | 11.96 | 9.585 | - |
| Enterprise Value (EV) 1 | 316.5 | 35.43 | 11.96 | 9.585 | 9.585 |
| P/E ratio | -5.05 x | -0.73 x | -0.24 x | -0.41 x | -0.55 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 28.7 x | 1.29 x | 0.43 x | 0.27 x | 0.21 x |
| EV / Revenue | 28.7 x | 1.29 x | 0.43 x | 0.27 x | 0.21 x |
| EV / EBITDA | -9,183,478 x | -790,514 x | - | - | - |
| EV / FCF | -8,233,644 x | -820,372 x | - | - | - |
| FCF Yield | -0% | -0% | - | - | - |
| Price to Book | 2.17 x | 0.76 x | - | - | - |
| Nbr of stocks (in thousands) | 29,307 | 29,522 | 29,984 | 30,103 | - |
| Reference price 2 | 10.80 | 1.200 | 0.3990 | 0.3184 | 0.3184 |
| Announcement Date | 3/22/22 | 3/21/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 11.04 | 27.44 | 27.51 | 35.5 | 46.5 |
| EBITDA | - | -34.47 | -44.81 | - | - | - |
| EBIT | - | -35.37 | -46.48 | - | - | - |
| Operating Margin | - | -320.33% | -169.44% | - | - | - |
| Earnings before Tax (EBT) | - | -38.94 | -48.45 | - | - | - |
| Net income | -18.01 | -38.96 | -48.47 | - | - | - |
| Net margin | - | -352.78% | -176.68% | - | - | - |
| EPS 2 | -3.600 | -2.140 | -1.650 | -1.640 | -0.7800 | -0.5800 |
| Free Cash Flow | - | -38.44 | -43.18 | - | - | - |
| FCF margin | - | -348.11% | -157.4% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/16/21 | 3/22/22 | 3/21/23 | 3/28/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.786 | 3.078 | 5.636 | 5.655 | 6.675 | 9.469 | 6.316 | 8.652 | 5.564 | 6.977 | 6.9 | 8.4 | 9.9 | 10.3 |
| EBITDA | -9.235 | -11.81 | -12.53 | -14.11 | -10.8 | -7.372 | -10.46 | -7.443 | -9.491 | - | - | - | - | - |
| EBIT | -9.441 | -12.1 | -12.86 | -14.49 | -11.25 | -7.884 | -10.97 | -7.966 | -10.12 | - | - | - | - | - |
| Operating Margin | -338.87% | -393.01% | -228.23% | -256.18% | -168.55% | -83.26% | -173.7% | -92.07% | -181.9% | - | - | - | - | - |
| Earnings before Tax (EBT) | -9.82 | -12.49 | -13.19 | -14.82 | -12.31 | -8.126 | -11.12 | -8.283 | -10.62 | - | - | - | - | - |
| Net income | -9.824 | -12.49 | -13.19 | -14.83 | -12.31 | -8.132 | -11.12 | -8.44 | -11.2 | - | - | - | - | - |
| Net margin | -352.62% | -405.82% | -234.1% | -262.26% | -184.48% | -85.88% | -176.04% | -97.55% | -201.28% | - | - | - | - | - |
| EPS 2 | -0.3400 | -0.4300 | -0.4500 | -0.5000 | -0.4200 | -0.2800 | -0.3700 | -0.2800 | -0.3700 | -0.6100 | -0.2300 | -0.2100 | -0.1800 | -0.1700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/22/22 | 5/10/22 | 8/9/22 | 11/8/22 | 3/21/23 | 5/11/23 | 8/10/23 | 11/13/23 | 3/28/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -38.4 | -43.2 | - | - | - |
| ROE (net income / shareholders' equity) | - | -42.9% | -70.6% | - | - | - |
| ROA (Net income/ Total Assets) | - | -54.4% | -49.1% | - | - | - |
| Assets | - | 71.56 | 98.81 | - | - | - |
| Book Value Per Share | - | 4.980 | 1.570 | - | - | - |
| Cash Flow per Share | - | -2.010 | -1.310 | - | - | - |
| Capex | - | 1.85 | 4.47 | - | - | - |
| Capex / Sales | - | 16.79% | 16.29% | - | - | - |
| Announcement Date | 3/16/21 | 3/22/22 | 3/21/23 | 3/28/24 | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3184
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.20% | 9.58M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- TBIO Stock
- Financials Telesis Bio, Inc.
